BOSTON, MA, March 16, 2026 – HerAnova™ Lifesciences, a leader in non-invasive diagnostic

innovation for endometriosis and infertility in women’s health, today announced its participation in the Pacific Coast Reproductive Society (PCRS) 2026 Annual Meeting, taking place March 18–22, 2026, at The Westin Rancho Mirage Golf Resort & Spa in Rancho Mirage, California. Attendees are invited to visit the HerAnova team at Booth 604 to learn more about HerResolve™, the first and only commercially available non-invasive blood test developed to detect endometriosis.

This year’s conference theme, Reproductive Frontiers: Bridging Biology, Practice, and Possibility, reflects the ongoing evolution of reproductive medicine, connecting science with clinical innovation and improved patient outcomes. HerAnova will be presenting HerResolve™ to fertility professionals and researchers at a meeting where endometriosis and its intersection with infertility is increasingly central to clinical discussion.

“PCRS brings together some of the most forward-thinking minds in reproductive medicine, and we look forward to connecting with clinicians and researchers who share our commitment to advancing women’s health.” said Cory Dunn, M.S., M.Ed. Vice President of Marketing at HerAnova Lifesciences. “Endometriosis has long been one of the most underdiagnosed and undertreated conditions in women’s health. HerResolve™ was designed to support earlier detection of endometriosis in the very settings represented at this meeting — and we look forward to meaningful conversations about how it can support better patient outcomes,” said Jonathan Y. Zhao, PhD, CEO and co-founder of HerAnova Lifesciences.

Attendees are encouraged to visit Booth 604 to meet the HerAnova team and learn how HerResolve™ is helping to close the diagnostic gap for women with suspected endometriosis.

About HerResolve™

HerResolve™ is a multi-omic, blood-based diagnostic assay developed by HerAnova Lifesciences for the detection of endometriosis in symptomatic women of reproductive age. The test integrates microRNA, protein, and hormone biomarkers analyzed through a proprietary machine learning framework to generate a clinically actionable result. HerResolve™ is the first and only commercially available non-invasive blood test developed to detect endometriosis, currently accessible at select IVF and reproductive medicine centers across the United States.

About HerAnova Lifesciences

HerAnova Lifesciences Inc. is a biotechnology company committed to delivering non-invasive diagnostics and treatments designed to meet critical needs in endometriosis and infertility to improve women’s health. By integrating diagnostics, therapeutics, medical devices, and data

analytics, HerAnova aims to provide a one-stop solution for unmet needs in obstetrics and gynecology. Founded in March 2022 in Boston by experienced entrepreneurs and former multinational executives, HerAnova operates on a multinational model for its research, development, and commercialization initiatives.

Media Contact:

Madelyn De Los Santos

Putnam Insights LLC madelyn@putnaminsights.com